Status | Study |
Terminated |
Study Name: Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Condition: Multiple Myeloma Leukemia, Plasma Cell Date: 2012-08-03 Interventions: Drug: Carfilzomib Drug: Melphalan |
Completed |
Study Name: Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Condition: Primary Plasma Cell Leukemia Date: 2012-03-03 Interventions: Drug: Lenalidomide, dexamethasone Enrolled patients receiv |
Recruiting |
Study Name: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Condition: Multiple Myeloma Multiple Myeloma in Relapse Mantle Cell L Date: 2011-09-14 Interventions: Biological: SNS01-T 0.05 mg/kg |
Active, not recruiting |
Study Name: Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Condition: Myeloma Date: 2011-06-10 Interventions: Drug: Arry-520 Part 1A Startin |
Completed |
Study Name: Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Condition: Plasma Cell Leukemia Multiple Myeloma Date: 2011-03-29 Interventions: Drug: Bortezomib |
Completed |
Study Name: A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Condition: Multiple Myeloma, Plasma Cell Leukemia Date: 2010-11-24 Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous |
Recruiting |
Study Name: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Condition: B-Cell Prolymphocytic Leukemia Hypodiploidy Loss of Chromo Date: 2009-11-04 Interventions: Procedure: Allogeneic Bone Marrow Transplantation |
Completed |
Study Name: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Condition: Multiple Myeloma Plasma Cell Leukemia Date: 2009-01-09 Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous |
Terminated |
Study Name: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Condition: Multiple Myeloma Plasma Cell Leukemia Date: 2008-01-22 Interventions: Drug: Fludarabine/Busulfan x 4 days |
Completed |
Study Name: Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Condition: Multiple Myeloma Plasma Cell Leukemia Date: 2006-03-23 Interventions: Drug: Bortezomib the maximum t |